Lack of recurrence of imatinib-induced interstitial lung disease with nilotinib

Leukemia and Lymphoma

Volumn 53, Issue 2, 2012, Pages 332-333

  Delomas, Thomas ^a   Darné, Christian ^b   Besson, Caroline ^a,c  

^a BICÊTRE HOSPITAL   (France)

^b Service de Pneumologie   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYUREA; IMATINIB; NILOTINIB;

AGED; CASE REPORT; CHRONIC MYELOID LEUKEMIA; COMPUTER ASSISTED TOMOGRAPHY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; INTERSTITIAL LUNG DISEASE; LETTER; LEUKEMIA REMISSION; LEUKOCYTOSIS; LUNG EMPHYSEMA; MALE; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; RECIPROCAL CHROMOSOME TRANSLOCATION; RECURRENT DISEASE;

AGED; ANTINEOPLASTIC AGENTS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LUNG DISEASES, INTERSTITIAL; MALE; NEOPLASM RECURRENCE, LOCAL; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84856081887     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.606940     Document Type: Letter

References (6)

1. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-1037. (Pubitemid 32267972)
2. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specifi c inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038-1042. (Pubitemid 32267973)
3. O hnishi K, Sakai F, Kudoh S, et al. Twenty-seven cases of druginduced interstitial lung disease associated with imatinib mesylate. Leukemia 2006;20:1162-1164. (Pubitemid 43797313)
4. Seki N, Ito A, Watanabe K, et al. Irreversible imatinib-induced pneumonitis following long-term imatinib administration. Intern Med 2007;46:1941-1942.
5. Bergeron A, Réa D, Levy V, et al. Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series. Am J Respir Crit Care Med 2007;176:814-818. (Pubitemid 47598483)
6. Swords R, Mahalingam D, Padmanabhan S, et al. Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib. Drug Des Devel Ther 2009;3:89-101.